Marshall S, Hujer A M, Rojas L J,et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in enterobacteriaceae?[J].Antimicrob Agents Chemother,2017,61(4):eco2243-16.
[2]
Zou C,Wei J, Shan B, et al. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant enterobacteriaceae isolates collected from three secondary hospitals in southwest china between 2018 and 2019[J]. Infect Drug Resist,2020,12(13):3563-3568.
Mojica M F, Ouellette C P, Leber A, et al. successful treatment of bloodstream infection due to metallo-β-lactamase-producing stenotrophomonasmaltophilia in a renaltransplant patient[J].Antimicrob Agents Chemother,2016,60(9):5130-5134.
[5]
Benchetrit L, Mathy V, Armand L L, et al. Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases[J].Int J Antimicrob Agents,2020,55(1):105842.
[6]
Cairns K A, Hall V, Martin G E, et al. Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: a case series and literature review[J]. Transpl Infect Dis,2021,23(2):e13510.
[7]
Yasmin M, Fouts D E, Jacobs M R, et al. Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant enterobacter sp. carrying both klebsiella pneumoniae carbapenemase-4 and new delhimetallo-β-lactamase-1[J]. Clin Infect Dis,2020,71(4):1095-1098.
[8]
Falcone M, Daikos G L, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase-producing enterobacterales[J]. Clin Infect Dis,2021,72(11):1871-1878.
[9]
Paul M, Daikos G L, Durante M E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial[J]. Lancet Infect Dis,2018,18(4):391-400.
[10]
Motsch J, Murta C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections[J]. Clin Infect Dis,2020,70(9):1799-1808.
[11]
Li J, Lovern M, Green M L, et al. Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups[J]. Clin Transl Sci,2019,12(2):151-163.
[12]
Cornely O A, Cisneros J M, Torre C J, et al. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study[J]. J Antimicrob Chemother,2020,75(3):618-627.
[13]
Lodise T P, Smith N M, O'Donnell N, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing enterobacteriaceae using a hollow-fibre infection model[J]. J Antimicrob Chemother,2020,75(9):2622-2632.
[14]
Li P, Lin Y, Hu X, et al. Characterization of blaNDM-1-and blaSHV-12-Positive IncX3 Plasmid in an enterobacter hormaechei new sequence type 1000 from china[J]. Infect Drug Resist,2020,13:145-153.
Yin D, Lin Y, Li Z, et al. Characterization of a Novel NDM-5-harboring plasmid from a carbapenem-resistant escherichia coli isolate from china[J]. Infect Drug Resist,2020,13:3929-3935.
2023, Vol. 34 
